Neurocrine Bioscienc (NQ: NBIX )

120.17 -1.04 (-0.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 868,976
Open 122.20
Bid (Size) 112.00 (1)
Ask (Size) 123.25 (1)
Prev. Close 121.21
Today's Range 119.85 - 122.75
52wk Range 103.63 - 157.98
Shares Outstanding 100,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them. 
Via Benzinga

Performance

YTD
-8.78%
-8.78%
1 Month
-18.10%
-18.10%
3 Month
-10.79%
-10.79%
6 Month
-13.30%
-13.30%
1 Year
+9.98%
+9.98%

More News

Read More
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Neurocrine Biosciences Stock Was Tumbling This Week
Via The Motley Fool
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Via Benzinga
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
Via Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Via Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
Via Benzinga
NASDAQ:NBIX is not too expensive for the growth it is showing.
Via Chartmill
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
Via Investor's Business Daily
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Via Benzinga
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Via Chartmill
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
Via PressReach
Exposures Product Safety
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
Via Chartmill
So Much For Expecting The Fed To Stick The Landing
Via Talk Markets
Topics Economy
Exposures Interest Rates
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
NASDAQ:NBIX, a growth stock which is not overvalued.
Via Chartmill
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio?
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Via Benzinga
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.